Skip to main content

 

Select a location

North America

  • US
  • Canada (EN | FR)

Latin America

  • Brazil
  • Colombia
  • Mexico

Asia PaCific

  • Australia
  • Japan

Europe & MENA

  • Austria & Switzerland
  • Benelux
  • Central Eastern Europe
  • France
  • Germany
  • Greece
  • Italy
  • Middle East & North Africa
  • Nordic & Baltic countries
  • Russia
  • Spain
  • United Kingdom

Locations

  • Home

Countries: ▼

Menu utilisateur

  • Contact us
  • Foundation
Home
Home
Menu
  • About us
    • Our history
    • Rare Diseases & Orphan Drugs
    • Recordati
    • Capabilities
    • Manufacturing plant
    • Executive Management Team
    • Collaborations
    • Gender equity index
    • Join us
  • Patient focus
    • Acromegaly
    • Acute porphyria
    • Cushing’s Disease and Syndrome
    • Cutaneous T-Cell Lymphoma
    • Cystic Fibrosis
    • Homocystinuria
    • Homozygous Familial Hypercholesterolemia
    • Hyperammonaemia
    • HRNB
    • iMCD
    • Nephropathic cystinosis
    • Patent Ductus Arteriosus
    • Phenylketonuria
    • Rare Cancers
    • Renal Cell Carcinoma
    • Vitamin E deficiency in chronic cholestasis
    • Wilson's disease
  • Products
  • R&D
    • Pipeline
    • The Arrigo Recordati Prize
  • Clinical Studies
    • Endocrinology

Breadcrumb

  1. Home
  2. News

News

  • Twitter
  • Facebook
  • Linked in
  • Mail

RECORDATI BOARD APPROVES THE 2023 ACCOUNTS, CONFIRMING STRONG PRELIMINARY RESULTS: REVENUE € 2,082.3M, EBITDA(1) € 769.6M, ADJUSTED NET INCOME(2) € 524.6M 2023 PROPOSED DIVIDEND € 1.20 (+4.3%)

03/19/2024
  Read more here  
  Read more here  

FIRST NINE MONTHS 2023 AHEAD OF PLAN: REVENUE +13.0%, EBITDA +15.4%, ADJUSTED NET INCOME +14.2%. 2025 REVENUE AND PROFITS EXPECTED TO EXCEED TARGETS SET IN FEBRUARY 2023

01/30/2024
  Read more here  
  Read more here  

FIRST HALF 2023 RESULTS CONFIRM STRONG MOMENTUM OF THE GROUP: REVENUE +17.0%, EBITDA +21.3%, ADJUSTED NET INCOME +27.9%. RECENT TRANSACTION WITH GSK FURTHER STRENGTHENS SPC UROLOGY FRANCHISE

07/29/2023
  Read more here  
  Read more here  

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 2
  • Current page 3
  • Page 4
  • Page 5
  • …
  • Next page Next ›
  • Last page Last »

Logo rrd 2023

Twitter  Linkedin

Informations

  • Legal Information
  • Corporate Compliance

® 2025 Recordati Rare Diseases All rights reserved.

Tweets by RecordatiD
  • About us
    • Our history
    • Rare Diseases & Orphan Drugs
    • Recordati
    • Capabilities
    • Manufacturing plant
    • Executive Management Team
    • Collaborations
    • Gender equity index
    • Join us
  • Patient focus
    • Acromegaly
    • Acute porphyria
    • Cushing’s Disease and Syndrome
    • Cutaneous T-Cell Lymphoma
    • Cystic Fibrosis
    • Homocystinuria
    • Homozygous Familial Hypercholesterolemia
    • Hyperammonaemia
    • HRNB
    • iMCD
    • Nephropathic cystinosis
    • Patent Ductus Arteriosus
    • Phenylketonuria
    • Rare Cancers
    • Renal Cell Carcinoma
    • Vitamin E deficiency in chronic cholestasis
    • Wilson's disease
  • Products
  • R&D
    • Pipeline
    • The Arrigo Recordati Prize
  • Clinical Studies
    • Endocrinology